logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Kesmalea Therapeutics Appoints Robert Johnson As Chief Executive Officer

Nov 07, 2024•about 1 year ago

Position

Chief Executive Officer

Company

Kesmalea Therapeutics

Robert Johnson
LondonBiopharmaTherapeuticsBiotechnologyHealth Care

Description

Kesmalea Therapeutics has announced the appointment of Robert Johnson as its Chief Executive Officer. Johnson will lead the company’s growth phase, focusing on a new small molecule approach to targeted protein degradation. The company aims to address the challenges associated with large protein degraders and broaden the applications of targeted protein degradation into important disease areas.

Company Information

Company

Kesmalea Therapeutics

Location

London, England, United Kingdom

About

Kesmalea Therapeutics is a biopharmaceutical company focused on developing a pipeline of novel therapeutics based on transforming large protein degraders into small molecules. Their proprietary technology, SELFTAC®, aims to address challenges in targeted protein degradation to enable oral dosing and central nervous system penetration.

Related People

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months